339 related articles for article (PubMed ID: 34963239)
21. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
22. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
23. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer.
Ouyang R; Wu S; Zhang B; Wang T; Yin B; Huang J; Wei W; Huang M; Zhang M; Wang Y; Wang F; Hou H
Cancer Biomark; 2021; 32(3):401-409. PubMed ID: 34151844
[TBL] [Abstract][Full Text] [Related]
25. Application Value Analysis of Seven-Autoantibody Panel in the Lung Cancer Screening in Yunnan.
Li W; Sun Y; Xu N
Comput Intell Neurosci; 2022; 2022():2368155. PubMed ID: 35832243
[TBL] [Abstract][Full Text] [Related]
26. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.
Dal Bello MG; Filiberti RA; Alama A; Orengo AM; Mussap M; Coco S; Vanni I; Boccardo S; Rijavec E; Genova C; Biello F; Barletta G; Rossi G; Tagliamento M; Maggioni C; Grossi F
J Transl Med; 2019 Mar; 17(1):74. PubMed ID: 30849967
[TBL] [Abstract][Full Text] [Related]
27. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
28. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
29. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
Chen ZQ; Huang LS; Zhu B
Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic value of serum tumor markers in differentiating malignant from benign solitary pulmonary nodules].
Ni LF; Liu XM
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):707-10. PubMed ID: 25331391
[TBL] [Abstract][Full Text] [Related]
31. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
32. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
33. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
34. [Auxiliary Diagnostic Value of Tumor Markers in the Cerebrospinal Fluid and Blood for Leptomeningeal Metastasis from Non-small Cell Lung Cancer].
Lin Y; Li H; Huang M; Yin Z; Wu J
Zhongguo Fei Ai Za Zhi; 2020 Jun; 23(6):516-525. PubMed ID: 32517459
[TBL] [Abstract][Full Text] [Related]
35. The Serum Tumor Markers in Combination for Clinical Diagnosis of Lung Cancer.
Wu H; Wang Q; Liu Q; Zhang Q; Huang Q; Yu Z
Clin Lab; 2020 Mar; 66(3):. PubMed ID: 32162867
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer.
Hongwei Yao ; Lixin Wen ; Ziyan Li ; Chunwei Xia
Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):57-62. PubMed ID: 37605590
[TBL] [Abstract][Full Text] [Related]
37. The role of seven tumor-associated autoantibodies in the diagnosis, staging and treatment guidance of lung cancer.
Ma H; Wu T; Zhang Q; Ding Q
BMC Pulm Med; 2024 May; 24(1):250. PubMed ID: 38773432
[TBL] [Abstract][Full Text] [Related]
38. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
Yang-Chun F; Min F; Di Z; Yan-Chun H
Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
